- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: IgA deficiency.
Displaying page 1 of 1.
EudraCT Number: 2019-001118-40 | Sponsor Protocol Number: NL69183.xxx.19 | Start Date*: 2019-08-22 |
Sponsor Name:Department of Pulmonology | ||
Full Title: Response to pneumococcal polysaccharide vaccination in healthy adults | ||
Medical condition: immunodeficiency | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003125-21 | Sponsor Protocol Number: P170915J | Start Date*: 2020-03-23 |
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | ||
Full Title: EFFECT OF INTRAVENOUS IRON SUPPLEMENTATION ON CELIAC DISEASE REMISSION IN PATIENTS WITH IRON DEFICIENCY AND INTESTINAL VILLOUS ATROPHY: A RANDOMIZED TRIAL | ||
Medical condition: Celiac patients with iron deficiency and intestinal villous atrophy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020048-36 | Sponsor Protocol Number: HGT-HIT-045 | Start Date*: 2011-01-31 | |||||||||||
Sponsor Name:Shire HGT, Inc | |||||||||||||
Full Title: A Phase I/II, Randomized, Safety and Ascending Dose Ranging Study of Intrathecal Idursulfase-IT administered in conjunction with intravenous Elaprase in Pediatric Patients with Hunter Syndrome and ... | |||||||||||||
Medical condition: Treatment of Hunter syndrome and cognitive impairment | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005001-26 | Sponsor Protocol Number: 20-773/M | Start Date*: 2021-12-24 |
Sponsor Name:UMC Utrecht | ||
Full Title: Influencing Progression of Airway Disease in Primary Antibody Deficiency | ||
Medical condition: Primary antibody deficiency: - Unclassified antibody deficiency (unPAD) - IgA deficiency - Specific polysaccharide antibody deficiency (SPAD) - IgG subclass deficiency (IgSD) - Common variable immu... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001484-39 | Sponsor Protocol Number: 444563/022 | Start Date*: 2015-06-11 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated huma... | ||
Medical condition: Rotavirus Gastroenteritis | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2021-001040-10 | Sponsor Protocol Number: CoVVac | Start Date*: 2021-04-26 | |||||||||||
Sponsor Name:Medical University of Graz | |||||||||||||
Full Title: Humoral and cellular immune response to COVID-19 vaccines in immunocompromised and healthy individuals – The CoVVac study | |||||||||||||
Medical condition: Active immunisation to prevent COVID-19 in immunocompromised individuals. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001472-22 | Sponsor Protocol Number: IMUNOR-201501 | Start Date*: 2017-03-14 | |||||||||||
Sponsor Name:ImunomedicA, a.s. | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Study Assessing Efficacy and Safety of the IMUNOR® Therapy Versus Placebo in Patients with Recurrent Vulvovaginit... | |||||||||||||
Medical condition: Recurrent vulvovaginitis episodes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: SK (Completed) CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000673-68 | Sponsor Protocol Number: 16IC17 | Start Date*: 2018-10-09 | |||||||||||
Sponsor Name:Great Ormond Street Hospital for Children NHS Trust | |||||||||||||
Full Title: Phase I/II study of lentiviral gene transfer for SCID-X1 with low dose targeted busulfan | |||||||||||||
Medical condition: Severe combined immunodeficiency disorder (SCID) is a heterogeneous group of inherited disorders characterized by a profound reduction or absence of T lymphocyte function, resulting in lack of both... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000917-38 | Sponsor Protocol Number: CBPR277X2101 | Start Date*: 2011-09-14 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: A first–in-human study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multip... | ||||||||||||||||||
Medical condition: Part 2: Atopic Dermatitis (AD) Part 3: Netherton Syndrome (NS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) NL (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
